Company Profile
Ventyx Biosciences, Inc. Stock Price, News & Analysis
- Ticker:
- VTYX
- Exchange:
- NASDAQ
- Sector:
- Small Molecule Drugs
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for VTYX.
Company overview
Business overview
Ventyx Biosciences is an immunology company building small-molecule therapies for inflammatory and autoimmune diseases.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Ventyx sits in early-stage biopharmaceuticals.
Business Model Characteristics
The company relies on clinical proof-of-concept, dose selection, and the chance to build a differentiated inflammation pipeline.
Position Within the Biotechnology Landscape
Ventyx is a catalyst-driven immunology name whose valuation depends heavily on clinical data quality.
Future catalysts
Ventyx's catalysts are its inflammation programs, especially the NLRP3 and related assets that still need human proof. The stock remains highly data-sensitive because the platform is still early.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
- 03
- 04
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Ventyx Biosciences, Inc. do?
Ventyx Biosciences is an immunology company building small-molecule therapies for inflammatory and autoimmune diseases.
On which exchange is VTYX stock listed?
Ventyx Biosciences, Inc. (VTYX) is associated with NASDAQ, United States, Small Molecule Drugs.
What is Ventyx?
Ventyx's catalysts are its inflammation programs, especially the NLRP3 and related assets that still need human proof.
Which conditions is Ventyx Biosciences, Inc. targeting with Ventyx?
Ventyx Biosciences, Inc. is associated with immunology, inflammatory disease based on its company overview and current catalyst commentary.
How does Ventyx Biosciences, Inc. describe recent progress with Ventyx?
Ventyx's catalysts are its inflammation programs, especially the NLRP3 and related assets that still need human proof.
What is Biosciences?
Ventyx Biosciences is an immunology company building small-molecule therapies for inflammatory and autoimmune diseases.
What should investors watch for with Biosciences?
Ventyx's catalysts are its inflammation programs, especially the NLRP3 and related assets that still need human proof. The stock remains highly data-sensitive because the platform is still early.
What is NLRP3?
Ventyx's catalysts are its inflammation programs, especially the NLRP3 and related assets that still need human proof.